Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC88473 Phase 1 Study in Healthy, Obese, and T2DM Subjects
NCT05943886Phase 1Completed
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC88473 in obesity and type 2 diabetes mellitus (T2DM) (15 arms). Primary endpoints: Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 43, Maximum Serum Concentration (Cmax) at Day 14 and 1 more. Started Aug 2021; status: completed.
02
Drugs
HEC88473
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05943886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943886.